Dr. Mark Kris, MD or Memorial Sloan Kettering discuss the role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.
Advertisement
The role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.
By Editor